中文

Journal Publications

[1]Deng F, Chu X, Shi W, Xiao G, Tanzhu G, Niu L, Zhang Z, Zhou R, Yang G. Radiogenomic modeling of EGFR mutation status in brain metastases from lung adenocarcinoma: a multicenter study with biological interpretability. NPJ Digit Med. 2026 Jul 6. doi: 10.1038/s41746-026-02931-9
[2]Tanzhu GL, Chen L, Ning JY, Xiao G, Wen S, Wang C, Wen H, Zhang KQ, Yang J, Jia MY, Deng HB, Marti TM, Lockman PR, Zhou RR. Crosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances. Mil Med Res. 2026;13(1):100047. doi: 10.1016/j.mmr.2026.100047
[3]Peng H, Tanzhu G, Shi W, Xiao G, Zeng Q, Chen L, Wan X, Jing D, Deng H, Marti TM, Fu J, Zhou R. Lactate-activated astrocytes promote NSCLC brain metastasis through extracellular vesicle-mediated miR-8085/TRIM67/ELK1 signaling axis. Cell Mol Biol Lett. 2026 May 31;31(1):138. doi: 10.1186/s11658-026-00957-1
[4]Liao R, Yu Q, Huang Y, He H, Song M, Gao X, Shen L, Tao Y, Li L, Xiao G, Kong R, Wang C, Huang S, Zhang X, Xu Z, Zhou R, Yang Z, Peng Y. Integrative multi-omics profiling reveals distinct evolutionary and immunogenic features of brain oligometastasis in lung adenocarcinoma. Genome Med. 2026 Apr 30;18(1):82. doi: 10.1186/s13073-026-01664-4
[5]Tanzhu G, Peng H, Chen L, Xiao G, Ning J, Chen L, Zhou R. Tumor treating fields combined with ionizing radiation inhibit the malignant phenotype of lung cancer brain metastasis cells by suppressing DNA damage repair pathways. Brain Stimul. 2025 Sep-Oct;18(5):1426-1440. doi: 10.1016/j.brs.2025.07.014
[6]Li H, Chen K, Gong L, Qin J, Jin Y, Zhou R, Huang Z, Xu Y, Xu X, He J, Zhu J, Yu S, Lu H, Xu Y, Yu X, Han G, Chen J, Tan W, Lou G, Ren B, Chen X, Zhang D, Wang W, Shi X, Xie F, Zhao J, Han N, Li B, Fan Y. High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 Jun 26:e251779. doi: 10.1001/jamaoncol.2025.1779
[7]Zeng Q, Liu M, Wang Z, Zhou R, Ai K. Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy. Mol Cancer. 2025 Jun 11;24(1):176. doi: 10.1186/s12943-025-02366-yIF: 27.7 Q1 . PMID: 40500702
[8]Lu R, Wang Z, Tian W, Shi W, Chu X, Zhou R. A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer. Sci Rep. 2025 Feb 27;15(1):7036. doi: 10.1038/s41598-025-91863-7. PMID: 40016281
[9]Deng F, Xiao G, Tanzhu G, Chu X, Ning J, Lu R, Chen L, Zhang Z, Zhou R. Predicting Survival Rates in Brain Metastases Patients from Non-Small Cell Lung Cancer Using Radiomic Signatures Associated with Tumor Immune Heterogeneity. Adv Sci (Weinh). 2025 Jan 22:e2412590. doi: 10.1002/advs.202412590.
[10]Tanzhu G, Chen L, Ning J, Xue W, Wang C, Xiao G, Yang J, Zhou R. Metastatic brain tumors: from development to cutting-edge treatment. MedComm (2020). 2024 Dec 20;6(1):e70020. doi: 10.1002/mco2.70020.
[11]Xiao G, Tanzhu G, Gao X, Li L, Liu Z, Xia X, Zhou R. An immune scoring system predicts prognosis and immune characteristics in lung adenocarcinoma brain metastases by RNA sequencing. Acta Neuropathol Commun. 2024 Nov 26;12(1):181. doi: 10.1186/s40478-024-01895-9
[12]Zeng Q, Chu X, Xiao G, Zhang J, Zhang Y, Long B, Yang L, Tan Z, Zhou R#. The Optimal Radiotherapy Strategy for Patients With Small Cell Lung Cancer and Brain Metastasis: A Retrospective Analysis. CNS Neurosci Ther. 2024 Nov;30(11):e70102. doi: 10.1111/cns.70102. PMID: 39500635
[13]Chu X, Tian W, Ning J, Zhou R#. Efficacy and Safety of Personalized Optimal PD-(L)1 Combinations in Advanced NSCLC: A Network Meta-Analysis. J Natl Cancer Inst. 2024 Oct 1;116(10):1571-1586.
[14]Tian W, Niu L, Shi Y#, Li S, Zhou R#. First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis. Ther Adv Med Oncol. 2024 May 30;16:17588359241255613. doi: 10.1177/17588359241255613. PMID: 38827178
[15]Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, Zhai Z, Tanzhu G, Yang J, Zhou R. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Ther. 2024 Jul 5;9(1):170.
[16]Ning J, Chen L, Zeng Y, Xiao G, Tian W, Wu Q, Tang J, He S, Tanzhu G, Zhou R#. The scheme, and regulative mechanism of pyroptosis, ferroptosis, and necroptosis in radiation injury. Int J Biol Sci. 2024 Mar 3;20(5):1871-1883. doi: 10.7150/ijbs.91112. PMID: 38481804.
[17]Niu L, Wu H, Gao R, Chen L, Wang J, Duan H, Long Y, Xie Y, Zhou Q, Zhou R. Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT. J Cancer Res Clin Oncol. 2024 Feb 19;150(2):94. doi: 10.1007/s00432-023-05538-9 PMID: 38369644
[18]Tian W, Ning J, Chen L, Zeng Y, Shi Y, Xiao G, He S, Tanzhu G, Zhou R#. Cost-effectiveness of tumor-treating fields plus standard therapy for advanced non-small cell lung cancer progressed after platinum-based therapy in the United States. Front Pharmacol. 2024 Feb 5;15:1333128. doi: 10.3389/fphar.2024.1333128. PMID: 38375030
[19]Shi, W., Tanzhu, G., Chen, L., Ning, J., Wang, H., Xiao, G., Peng, H., Jing, D., Liang, H., Nie, J., Yi, M., Zhou R#. (2024). Radiotherapy in Preclinical Models of Brain Metastases: A Review and Recommendations for Future Studies. International Journal of Biological Sciences, 2024 Jan 1; 20(2), 765-783. doi: 10.7150/ijbs.91295. PMID: 38169621.
[20]Mohammed N, Xiao EH, Mohsen S, Xiong Z, Zhou R#. PD-1/PD-L1 inhibitor treatment and its impact on clinical imaging in non-small cell lung cancer: a systematic review and meta-analysis of immune-related adverse events. Front Oncol. 2023 Sep 29;13:1191681. doi: 10.3389/fonc.2023.1191681. PMID: 37841435; PMCID: PMC10571717.

total80 1/4

firstpreviousnext last Page

周蓉蓉

Zip Code:
Fax:
Postal Address:
Office Phone:
Email:

Central South University All rights reserved 湘ICP备05005659号-1

Click:

The Last Update Time:..